Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams-075

Gaëlle Laboure (1) , Marie-Cecile Parrens (1) , Anjarasoa Tsaranazy (1) , Magali Bordier (1) , Steven Le Gouill (2) , Vincent Delwail (3) , Rémy Gressin (4, 5) , Jerome Cornillon (6) , Gandhi Damaj (7) , Charles Yves Foussard (8) , Hervé Maisonneuve (9) , Eric Deconinck (10) , Guillaume Cartron (11, 12) , François Dreyfus (13) , Emmanuel Gyan (14, 15) , Laurent Sutton (16) , Nadine Morineau (17) , Magda Alexis (18) , Anne Banos (19) , Diane Damotte (20, 21) , Anne Moreau (2) , Françoise Kraeber-Bodéré (22, 23, 24) , Delphine Rossille (25, 26) , Thierry Fest (26) , Thierry Lamy (27, 26) , Noel Milpied (28)

1 CHU Bordeaux
2 CHU Nantes - Centre Hospitalier Universitaire de Nantes
3 Service d'Anatomie et de Cytologie Pathologiques [Poitiers]
4 INSERM U823 - Institut d'oncologie/développement Albert Bonniot de Grenoble
5 Service d'hématologie clinique
6 CHU ST-E - Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne]
7 CHU Caen
8 CHU Angers - Centre Hospitalier Universitaire d'Angers
9 Service d'hématologie
10 Service d'Hématologie [CHRU Besançon]
11 CHU Montpellier
12 DIMNP - Dynamique des interactions membranaires normales et pathologiques
13 Service d'hématologie
14 Service d'hématologie
15 CIC - Tours
16 Hôpital d'Argenteuil
17 CCS - Centre Catherine-de-Sienne [Nantes]
18 CHRO - Centre Hospitalier Régional d'Orléans
19 Hôpital de Bayonne
20 CRC - Centre de Recherche des Cordeliers
21 Biologie Pharmacie Pathologie
22 Service de Médecine Nucléaire [Nantes]
23 CRCNA - Centre de Recherche en Cancérologie Nantes-Angers
24 Service de médecine nucléaire
25 Laboratoire d'Hematologie
26 MiCa - Microenvironnement et cancer
27 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
28 Service d'Hématologie et Thérapie Cellulaire

The prognostic value of COO classification by immunohistochemistry (IHC) for de novo untreated advanced DLBCL remains controversial after Rituximab-based frontline therapy. Other biomarkers such as BCL2 or MYC protein expression have been proposed to predict survival. IHC characteristics were investigated in a large multicenter randomized study.

Domaines: Cancer; Hématologie; Immunothérapie

Gaëlle Laboure, Marie-Cecile Parrens, Anjarasoa Tsaranazy, Magali Bordier, Steven Le Gouill, et al.. Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams-075. 55th Annual Meeting and Exposition of the American-Society-of-Hematology, Dec 2013, La Nouvelle Orléans, United States. 126 (23), pp.3920, 2015. ⟨hal-01290432⟩